| Drug General Information |
| Drug ID |
D02MMF
|
| Former ID |
DIB013080
|
| Drug Name |
FP-1097
|
| Synonyms |
Urinary incontinence therapy, FemmePharma
|
| Indication |
Urinary incontinence [ICD9: 788.3; ICD10:N39.3, N39.4, R32]
|
Phase 2 |
[1]
|
|---|
| Company |
FemmePharma Inc
|
| Target and Pathway |
| Target(s) |
Muscarinic acetylcholine receptor M1 |
Target Info |
Antagonist |
[2]
|
|---|
| Muscarinic acetylcholine receptor M2 |
Target Info |
Antagonist |
[2]
|
|
KEGG Pathway
|
Calcium signaling pathway
|
|
cAMP signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
PI3K-Akt signaling pathway
|
|
Cholinergic synapse
|
|
Regulation of actin cytoskeletonhsa04020:Calcium signaling pathway
|
|
Regulation of actin cytoskeleton
|
|
PANTHER Pathway
|
Alzheimer disease-amyloid secretase pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Muscarinic acetylcholine receptor 1 and 3 signaling pathwayP00003:Alzheimer disease-amyloid secretase pathway
|
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Muscarinic acetylcholine receptor 2 and 4 signaling pathway
|
|
PathWhiz Pathway
|
Muscle/Heart Contraction
|
|
Reactome
|
Muscarinic acetylcholine receptors
|
|
G alpha (q) signalling eventsR-HSA-390648:Muscarinic acetylcholine receptors
|
|
G alpha (i) signalling events
|
|
WikiPathways
|
Monoamine GPCRs
|
|
Calcium Regulation in the Cardiac Cell
|
|
Regulation of Actin Cytoskeleton
|
|
GPCRs, Class A Rhodopsin-like
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
Secretion of Hydrochloric Acid in Parietal Cells
|
|
GPCR ligand binding
|
|
GPCR downstream signalingWP706:SIDS Susceptibility Pathways
|
|
GPCR downstream signaling
|
|
GPCRs, Other
|
| References |
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019662) |
|---|
| REF 2 | Clinical pipeline report, company report or official report of FemmePharma. |
|---|
